359 related articles for article (PubMed ID: 29109728)
1. Invariant Natural Killer T Cells in Immune Regulation of Blood Cancers: Harnessing Their Potential in Immunotherapies.
Lam PY; Nissen MD; Mattarollo SR
Front Immunol; 2017; 8():1355. PubMed ID: 29109728
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy.
Bedard M; Salio M; Cerundolo V
Front Immunol; 2017; 8():1829. PubMed ID: 29326711
[TBL] [Abstract][Full Text] [Related]
3. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
4. Functions of CD1d-Restricted Invariant Natural Killer T Cells in Antimicrobial Immunity and Potential Applications for Infection Control.
Kinjo Y; Takatsuka S; Kitano N; Kawakubo S; Abe M; Ueno K; Miyazaki Y
Front Immunol; 2018; 9():1266. PubMed ID: 29928278
[TBL] [Abstract][Full Text] [Related]
5. Combination of NKT14m and Low Dose IL-12 Promotes Invariant Natural Killer T Cell IFN-γ Production and Tumor Control.
Guan P; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708464
[TBL] [Abstract][Full Text] [Related]
6. Decreased invariant natural killer T-cell-mediated antitumor immune response in patients with gastric cancer.
Ascui G; Gálvez-Jirón F; Kramm K; Schäfer C; Siña J; Pola V; Cristi F; Hernández C; Garrido-Tapia M; Pesce B; Bustamante M; Fluxá P; Molina MC; Ribeiro CH
Immunol Cell Biol; 2020 Jul; 98(6):500-513. PubMed ID: 32189398
[TBL] [Abstract][Full Text] [Related]
7. Serial Stimulation of Invariant Natural Killer T Cells with Covalently Stabilized Bispecific T-cell Engagers Generates Antitumor Immunity While Avoiding Anergy.
Kharkwal SS; Johndrow CT; Veerapen N; Kharkwal H; Saavedra-Avila NA; Carreño LJ; Rothberg S; Zhang J; Garforth SJ; Jervis PJ; Zhang L; Donda A; Besra AK; Cox LR; Almo SC; Howell A; Evans EE; Zauderer M; Besra GS; Porcelli SA
Cancer Res; 2021 Apr; 81(7):1788-1801. PubMed ID: 33483371
[TBL] [Abstract][Full Text] [Related]
8. Activated invariant natural killer T cells directly recognize leukemia cells in a CD1d-independent manner.
Aoki T; Takami M; Takatani T; Motoyoshi K; Ishii A; Hara A; Toyoda T; Okada R; Hino M; Koyama-Nasu R; Kiuchi M; Hirahara K; Kimura MY; Nakayama T; Shimojo N; Motohashi S
Cancer Sci; 2020 Jul; 111(7):2223-2233. PubMed ID: 32324315
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the antitumor functions of invariant natural killer T cells using a soluble CD1d-CD19 fusion protein.
Das R; Guan P; Wiener SJ; Patel NP; Gohl TG; Evans E; Zauderer M; Nichols KE
Blood Adv; 2019 Mar; 3(5):813-824. PubMed ID: 30858151
[TBL] [Abstract][Full Text] [Related]
10. Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.
Shissler SC; Lee MS; Webb TJ
Front Immunol; 2017; 8():1447. PubMed ID: 29163518
[TBL] [Abstract][Full Text] [Related]
11. Invariant and noninvariant natural killer T cells exert opposite regulatory functions on the immune response during murine schistosomiasis.
Mallevaey T; Fontaine J; Breuilh L; Paget C; Castro-Keller A; Vendeville C; Capron M; Leite-de-Moraes M; Trottein F; Faveeuw C
Infect Immun; 2007 May; 75(5):2171-80. PubMed ID: 17353286
[TBL] [Abstract][Full Text] [Related]
12. Hiding lipid presentation: viral interference with CD1d-restricted invariant natural killer T (iNKT) cell activation.
Horst D; Geerdink RJ; Gram AM; Stoppelenburg AJ; Ressing ME
Viruses; 2012 Oct; 4(10):2379-99. PubMed ID: 23202469
[TBL] [Abstract][Full Text] [Related]
13. Cancer Immunotherapeutic Potential of NKTT320, a Novel, Invariant, Natural Killer T Cell-Activating, Humanized Monoclonal Antibody.
Patel NP; Guan P; Bahal D; Hashem T; Scheuplein F; Schaub R; Nichols KE; Das R
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560408
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Galactosylceramide/CD1d-Antibody Fusion Proteins Redirect Invariant Natural Killer T Cell Immunity to Solid Tumors and Promote Prolonged Therapeutic Responses.
Zhang L; Donda A
Front Immunol; 2017; 8():1417. PubMed ID: 29163493
[TBL] [Abstract][Full Text] [Related]
15. CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.
King LA; Lameris R; de Gruijl TD; van der Vliet HJ
Front Immunol; 2018; 9():1519. PubMed ID: 30013569
[TBL] [Abstract][Full Text] [Related]
16. Invariant natural killer T cells: bridging innate and adaptive immunity.
Van Kaer L; Parekh VV; Wu L
Cell Tissue Res; 2011 Jan; 343(1):43-55. PubMed ID: 20734065
[TBL] [Abstract][Full Text] [Related]
17. Harnessing invariant natural killer T cells to control pathological inflammation.
Bharadwaj NS; Gumperz JE
Front Immunol; 2022; 13():998378. PubMed ID: 36189224
[TBL] [Abstract][Full Text] [Related]
18. CD1d-restricted glycolipid antigens: presentation principles, recognition logic and functional consequences.
Florence WC; Bhat RK; Joyce S
Expert Rev Mol Med; 2008 Jul; 10():e20. PubMed ID: 18601810
[TBL] [Abstract][Full Text] [Related]
19. CD1d Expression and Invariant NKT Cell Responses in Herpesvirus Infections.
Chung BK; Priatel JJ; Tan R
Front Immunol; 2015; 6():312. PubMed ID: 26161082
[TBL] [Abstract][Full Text] [Related]
20. Human invariant NKT cells display alloreactivity instructed by invariant TCR-CD1d interaction and killer Ig receptors.
Patterson S; Chaidos A; Neville DC; Poggi A; Butters TD; Roberts IA; Karadimitris A
J Immunol; 2008 Sep; 181(5):3268-76. PubMed ID: 18713998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
